Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation

Nutrition

Volumn 17, Issue 9, 2001, Pages 751-755

  Barber, Matthew D ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cachexia; Cancer; Eicosapentaenoic acid; Fish oil

Indexed keywords

CYTOKINE; FISH OIL; IBUPROFEN; ICOSAPENTAENOIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVANCED CANCER; CACHEXIA; CANCER; CONFERENCE PAPER; ENERGY EXPENDITURE; HUMAN; NUTRITION; NUTRITIONAL SUPPORT; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CACHEXIA; DIETARY SUPPLEMENTS; FISH OILS; HUMANS; INFLAMMATION; NEOPLASMS; PANCREATIC NEOPLASMS;

EID: 0034838336     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(01)00631-1     Document Type: Conference Paper

References (95)

1. Epidemiology and risk factors in pancreatic cancer
2. Cancer statistics, 1999
3. Adjuvant therapy for pancreatic cancer
4. Changes in nutritional status associated with unresectable pancreatic cancer
5. The mechanisms and treatment of weight loss in cancer
6. The immediate causes of death in cancer
7. Causes of death in cancer patients
8. Prognostic effect of weight loss prior to chemotherapy in cancer patients
9. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy; a prospective, randomised study
10. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients
11. Uncomplicated starvation versus cancer cachexia
12. Hyperalimentation of the cancer patient with protein-calorie undernutrition
13. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer
14. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer
15. Energy expenditure in malnourished cancer patients
16. Effect of different tumor types on resting energy expenditure
17. Metabolic response to enteral food in different phases of cancer cachexia in rats
18. Measurement of total energy expenditure in patients with lung cancer and validation of the bicarbonate-urea method against whole-body indirect calorimetry
19. Insulin resistance in patients with cancer
20. Glucose metabolism in cachectic patients with colorectal cancer
21. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding
22. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer; the response to glucose infusion, parenteral feeding, and surgical resection
23. Cancer cachexia and protein metabolism
24. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer
25. Protein synthesis in muscle measured in vivo in cachectic patients with cancer
26. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover
27. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response
28. Fibrinogen synthesis is elevated in fasted cancer patients with an acute phase response
29. Liver export proteins and trauma
30. The acute phase response
31. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma
32. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer
33. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients
34. Fibrinogen levels correlate with stage of disease in patients with oesophageal cancer
35. Changes in nutritional, functional and inflammatory markers in advanced pancreatic cancer
36. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer
37. Acute-phase protein response and survival duration of patients with pancreatic cancer
38. Brünner Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer
39. Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states?
40. Liver export protein synthetic rates are increased by oral meal feeding in weight-losing cancer patients
41. Biology of cachexia
42. Tumour necrosis factor in man; clinical and biological observations
43. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines
44. Tumor necrosis factor and the acute metabolic response to tissue injury in man
45. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins
46. Acute-phase response of human hepatocytes; regulation of acute-phase protein synthesis by interleukin-6
47. Effects of human recombinant interleukin-1β on protein synthesis in rat tissues compared with a classical acute-phase reaction induced by turpentine
48. IL-8 and IL-6 are produced constitutively by human pancreatic cancer cell lines
49. Tumor necrosis factor not detectable in patients with clinical cancer cachexia
50. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer
51. Anti-TNF-α antibodies normalised body temperature and enhanced food intake in tumor-bearing rats
52. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma; effect on lymphoma growth and on B clinical symptoms
53. A polymorphism of the interleukin-1β gene influences survival in pancreatic cancer
54. Combined hormonal infusion simulates the metabolic response to injury
55. Both inflammatory and endocrine mediators stimulate host responses to sepsis
56. Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases
57. Peripheral tissue metabolism in cancer-bearing man
58. Characterisation of a cancer cachectic factor
59. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients
60. Mechanism of depletion of liver glycogen in cancer cachexia
61. Biological evaluation of a lipid mobilising factor (LMF) from the urine of cancer patients
62. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer
63. A randomised trial of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer
64. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy; a prospective, randomised study
65. Parenteral nutrition in patients receiving cancer chemotherapy
66. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients; a placebo-controlled, multicenter study
67. Methylprednisolone as palliative therapy for female terminal cancer patients
68. Controlled trial of Megestrol acetate for the treatment of cancer anorexia and cachexia
69. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer
70. Megestrol acetate in cancer anorexia and weight loss
71. Body-composition changes in patients who gain weight while receiving megestrol acetate
72. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced nonhormone-sensitive cancer
73. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumours
74. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients
75. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss
76. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients
77. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients
78. A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
79. Cardiovascular effects of n-3 fatty acids
80. Effects of changes in fat, fish and fiber intakes on death and myocardial reinfarction; Diet and Reinfarction Trial (DART)
81. Anticachectic and antitumour effect of eicosapentaenoic acid and its effect on protein turnover
82. Dietary fish oil suppresses human colon tumour growth in athymic mice
83. Dietary supplementation with eicosapentaenoic acid slows human pancreatic cancer growth in SCID mice
84. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells
85. Immunological effects of National Cholesterol Education Panel Step-2 diets with and without fish-derived n-3 fatty acid enrichment
86. The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable or fish oil
87. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6
88. Fish oil and plasma fibrinogen
89. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer
90. Inhibition of lipolysis and muscle protein degradation by EPA in cancer cachexia
91. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer
92. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalised malignancy. A randomised controlled trial
93. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer
94. Fish oil-enriched nutritional supplement attenuates progression of the acute phase response in weight-losing patients with advanced pancreatic cancer
95. The metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish oil-enriched nutritional supplement